Floatz logo

Irinotecan

Gastric or Gastroesophageal Junction Adenocarcinoma

UNICANCERSmall moleculePhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Gastric or Gastroesophageal Junction Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Eloxatin
Memorial Sloan Kettering Cancer Center
Phase 3BB
Pembrolizumab
Diwakar Davar
Phase 3BB
TRASTUZUMAB
UNICANCER
Phase 3BB
Ipilimumab
Memorial Sloan Kettering Cancer Center
Phase 1/2B
S-1
Tao Zhang
Phase 2CCC

View all 9 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →